ING to redeem Perpetual Capital Securities

ING announced today it will redeem USD 1,500 million of 5.750% Perpetual Additional Tier 1 Contingent Convertible Capital Securities (the “Perpetual Capital Securities”) on the call date of 16 November 2026, in line with ING’s goal to continuously optimise its capital structure.

The Perpetual Capital Securities (CUSIP 456837AR4/ISIN US456837AR44) will be redeemed in full in accordance with their terms, with payment to be made on 16 November 2026. The redemption price will be the principal amount of the Perpetual Capital Securities. Accrued and unpaid interest due on the redemption date will be paid in the usual manner to holders of record as of 13 November 2026. The paying agent for the Perpetual Capital Securities is The Bank of New York Mellon, London Branch 160 Queen Victoria Street London EC4V 4LA United Kingdom.

Any future decisions by ING as to whether it will exercise (or cause to be exercised) calls in respect of some or all of any series of its then outstanding debt securities will be made on an economic basis, taking into account the interests of all stakeholders. Other factors that ING will consider include prevailing market conditions, regulatory approval and capital requirements.

Note for editors
For further information on ING, please visit www.ing.com. Frequent news updates can be found in the Newsroom. Photos of ING operations, buildings and its executives are available for download at Flickr.

Press enquiries Investor enquiries
ING Group Media Relations ING Group Investor Relations
+31 20 576 5000 +31 20 576 6396
media.relations@ing.com Investor.Relations@ing.com

ING PROFILE
ING is a global financial institution with a strong European base, offering banking services through its operating company ING bank. The purpose of ING Bank is: empowering people to stay a step ahead in life and in business. ING Bank’s more than 60,000 employees offer retail and wholesale banking services to customers in over 100 countries.

ING Group shares are listed on the exchanges of Amsterdam (INGA NA, INGA.AS), Brussels and on the New York Stock Exchange (ADRs: ING US, ING.N).

ING aims to put sustainability at the heart of what we do. Our policies and actions are assessed by independent research and ratings providers, which give updates on them annually. ING’s ESG rating by MSCI has been upgraded from ‘AA’ to ‘AAA’ in October 2025. As of July 2026, in Sustainalytics’ view, ING’s management of ESG material risk is ‘Strong’ with an ESG risk rating of 16.7 (low risk). ING Group shares are also included in major sustainability and ESG index products of leading providers. Here are some examples: Euronext, STOXX, Morningstar and FTSE Russell.

IMPORTANT LEGAL INFORMATION
Elements of this press release contain or may contain information about ING Groep N.V. and/ or ING Bank N.V. within the meaning of Article 7(1) to (4) of EU Regulation No 596/2014 (‘Market Abuse Regulation’).

ING Group’s annual accounts are prepared in accordance with International Financial Reporting Standards as adopted by the European Union (‘IFRS- EU’). In preparing the financial information in this document, except as described otherwise, the same accounting principles are applied as in the 2025 ING Group consolidated annual accounts. All figures in this document are unaudited. Small differences are possible in the tables due to rounding.

Certain of the statements contained herein are not historical facts, including, without limitation, certain statements made of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Actual results, performance or events may differ materially from those in such statements due to a number of factors, including, without limitation: (1) changes in general economic conditions and customer behaviour, in particular economic conditions in ING’s core markets, including changes affecting currency exchange rates and the regional and global economic impact of the invasion of Russia into Ukraine and related international response measures (2) changes affecting interest rate levels (3) any default of a major market participant and related market disruption (4) changes in performance of financial markets, including in Europe and developing markets (5) fiscal uncertainty in Europe and the United States (6) discontinuation of or changes in ‘benchmark’ indices (7) inflation and deflation in our principal markets (8) changes in conditions in the credit and capital markets generally, including changes in borrower and counterparty creditworthiness (9) failures of banks falling under the scope of state compensation schemes (10) non-compliance with or changes in laws and regulations, including those concerning financial services, financial economic crimes and tax laws, and the interpretation and application thereof (11) geopolitical risks, political instabilities and policies and actions of governmental and regulatory authorities, including in connection with the invasion of Russia into Ukraine and other existing or emerging military conflicts, the risk of further military escalation, geopolitical tensions, trade restrictions and the related international response measures (12) legal and regulatory risks in certain countries with less developed legal and regulatory frameworks (13) prudential supervision and regulations, including in relation to stress tests and regulatory restrictions on dividends and distributions (also among members of the group) (14) ING’s ability to meet minimum capital and other prudential regulatory requirements (15) changes in regulation of US commodities and derivatives businesses of ING and its customers (16) application of bank recovery and resolution regimes, including write down and conversion powers in relation to our securities (17) outcome of current and future litigation, enforcement proceedings, investigations or other regulatory actions, including claims by customers or stakeholders who feel misled or treated unfairly, and other conduct issues (18) changes in tax laws and regulations and risks of non-compliance or investigation in connection with tax laws, including FATCA (19) operational and IT risks, such as system disruptions or failures, breaches of security, cyber-attacks, human error, changes in operational practices or inadequate controls including in respect of third parties with which we do business and including any risks as a result of incomplete, inaccurate, or otherwise flawed outputs from the algorithms and data sets utilized in artificial intelligence (20) risks and challenges related to cybercrime including the effects of cyberattacks and changes in legislation and regulation related to cybersecurity and data privacy, including such risks and challenges as a consequence of the use of emerging technologies, such as advanced forms of artificial intelligence and quantum computing (21) changes in general competitive factors, including ability to increase or maintain market share (22) inability to protect our intellectual property and infringement claims by third parties (23) inability of counterparties to meet financial obligations or ability to enforce rights against such counterparties (24) changes in credit ratings (25) business, operational, regulatory, reputation, transition and other risks and challenges in connection with climate change, diversity, equity and inclusion and other ESG-related matters, including data gathering and reporting and also including managing the conflicting laws and requirements of governments, regulators and authorities with respect to these topics (26) inability to attract and retain key personnel (27) future liabilities under defined benefit retirement plans (28) failure to manage business risks, including in connection with use of models, use of derivatives, or maintaining appropriate policies and guidelines (29) changes in capital and credit markets, including interbank funding, as well as customer deposits, which provide the liquidity and capital required to fund our operations, and (30) the other risks and uncertainties detailed in the most recent annual report of ING Groep N.V. (including the Risk Factors contained therein) and ING’s more recent disclosures, including press releases, which are available on www.ing.com.

This document may contain ESG-related material that has been prepared by ING on the basis of publicly available information, internally developed data and other third-party sources believed to be reliable. ING has not sought to independently verify information obtained from public and third-party sources and makes no representations or warranties as to accuracy, completeness, reasonableness or reliability of such information. This document may also discuss one or more specific transactions and/or contain general statements about ING’s ESG approach. The approach and criteria referred to in this document are intended to be applied in accordance with applicable law. Due to the fact that there may be different or even conflicting laws, the approach, criteria or the application thereof, could be different.

Materiality, as used in the context of ESG, is distinct from, and should not be confused with, such term as defined in the Market Abuse Regulation or as defined for Securities and Exchange Commission (‘SEC’) reporting purposes. Any issues identified as material for purposes of ESG in this document are therefore not necessarily material as defined in the Market Abuse Regulation or for SEC reporting purposes.  In addition, there is currently no single, globally recognized set of accepted definitions in assessing whether activities are “green” or “sustainable.” Without limiting any of the statements contained herein, we make no representation or warranty as to whether any of our securities constitutes a green or sustainable security or conforms to present or future investor expectations or objectives for green or sustainable investing. For information on characteristics of a security, use of proceeds, a description of applicable project(s) and/or any other relevant information, please reference the offering documents for such security.

This document may contain inactive textual addresses to internet websites operated by us and third parties. Reference to such websites is made for information purposes only, and information found at such websites is not incorporated by reference into this document. ING does not make any representation or warranty with respect to the accuracy or completeness of, or take any responsibility for, any information found at any websites operated by third parties. ING specifically disclaims any liability with respect to any information found at websites operated by third parties. ING cannot guarantee that websites operated by third parties remain available following the publication of this document, or that any information found at such websites will not change following the filing of this document. Many of those factors are beyond ING’s control.

Any forward-looking statements made by or on behalf of ING speak only as of the date they are made, and ING assumes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information or for any other reason.

This document does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States or any other jurisdiction.

Attachment

17 September 2026: Borregaard ASA (“Borregaard”, OSE ticker: BRG)

Borregaard Capital Markets Day (CMD) 2026 takes place today at Oslo Concert Hall, from 09:00 to 12:30 CEST. The event can be followed via webcast at https://www.borregaard.com/investors/ir-news/capital-markets-day-2026-borregaard. The presentation material is attached to this stock exchange announcement and is also available on Borregaard’s website.

Key highlights – Borregaard CMD 2026:

  •  Scaling specialisation and delivering greater value
  •  BioSolutions: Scaling proven winners through market leadership, technology and innovation
  •  BioMaterials: Further specialisation and higher value creation
  •  Global manufacturing: Enabling growth and competitiveness
  •  Finance: Ambitions for profitable growth

During the presentation, CEO Tom Erik Foss-Jacobsen will provide an update on Borregaard’s strategic priorities and outline how the company will continue to scale its specialisation strategy.

The EVP of BioSolutions and the EVP of Speciality Cellulose and Fine Chemicals will provide market updates, focusing on attractive growth opportunities and increased value creation. The EVP of Manufacturing and Technology will elaborate on how Borregaard’s global manufacturing platform supports growth and competitiveness.

CFO Per Bjarne Lyngstad will comment on financial performance and outline Borregaard’s ambitions for profitable growth.

Borregaard ASA
Sarpsborg, 17 September 2026

Contact:
Lotte Kvinlaug, Investor Relations Officer, +47 922 86 909

This information is subject to the disclosure requirements pursuant to Section 5 -12 of the Norwegian Securities Trading Act and requirements under the EU Market Abuse Regulation.

Attachment

17 September 2026

HARGREAVE HALE AIM VCT PLC
(the “Company”)

DRIS Issue Price

The reference price of a new Ordinary Share under the Company’s Dividend Re-investment Scheme (“DRIS”) for the special dividend announced on 13 August 2026 (the “Dividend”) has been set at 31.50p.  This is the last published ex-dividend NAV per Ordinary Share, as at close of business on 16 September 2026.

Further information regarding the DRIS offered in respect of the Dividend can be found in the DRIS Mandate (the “DRIS Mandate“) available on the Company’s website to view and/or download at https://www.hargreaveaimvcts.co.uk/document-library/. The DRIS Mandate is also available on the National Storage Mechanism website at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

The payment date of the Dividend and the allotment date of the new Ordinary Shares, to be issued pursuant to the DRIS (the “New Ordinary Shares”), is 30 September 2026. The date for admission and dealing of the New Ordinary Shares is expected to be on or around 7 October 2026.

END

For further information, please contact:

Canaccord Genuity Asset Management Limited
Abbe Martineau
aimvct@canaccord.com
+44 20 7523 4525

 

LEI: 213800LRYA19A69SIT31        

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS

Neuberger Private Equity Partners Announces Transaction in Own Shares

St Peter Port, Guernsey 17 September 2026

Neuberger Private Equity Partners Limited (“NBPE” or the “Company”) today announces details of Class A Shares bought back pursuant to general authority granted by shareholders of the Company on 11 June 2026 and the share buy-back agreement with Jefferies International Limited.

Transaction on London Stock Exchange

Date of purchase of Shares

16 September 2026
Number of Shares purchased

600,553 Class A Shares
Highest price/lowest price paid

£14.45 / £14.34
ISIN for the Shares GG00B1ZBD492

All Class A Shares bought back will be cancelled. Following the cancellation, the number of outstanding Class A Shares is 38,092,007‬. The Company also has 3,150,408 Class A shares held in treasury. For reporting purposes under the FCA’s Disclosure Guidance and Transparency Rules the market should use the figure of 38,092,007 voting rights when determining if they are required to notify their interest in, or a change to their interest in the Company.

For further information, please contact:

NBPE Investor Relations        +44 20 3214 9002
Luke Mason        NBPrivateMarketsIR@nb.com

Oak Group        +44 1481 723450

        NBPEP@oak.group

About Neuberger Private Equity Partners Limited

NBPE invests in direct private equity investments alongside market leading private equity firms globally. NB Alternatives Advisers LLC (the “Investment Manager”), an indirect wholly owned subsidiary of Neuberger Berman Group LLC, is responsible for sourcing, execution and management of NBPE. The vast majority of direct investments are made with no management fee / no carried interest payable to third-party GPs, offering greater fee efficiency than other listed private equity companies. NBPE seeks capital appreciation through growth in net asset value over time while paying a bi-annual dividend.

LEI number: 213800UJH93NH8IOFQ77

About Neuberger
Neuberger is an employee-owned, private, independent investment manager founded in 1939 with approximately 3,000 employees across 26 countries. The firm manages $567 billion of equities, fixed income, private markets, real estate and hedge fund portfolios for global institutions, advisors and individuals. Neuberger’s investment philosophy is founded on active management, fundamental research and engaged ownership. The firm is proud to be recognized for its commitment to its two constituents, clients and employees. Again this past year, we were named Best Asset Manager for Institutional Investors in the US (Crisil Coalition Greenwich) and the #1 Best Place to Work in Money Management (Pensions & Investments, firms with more than 1,000 employees). Neuberger has no corporate parent or unaffiliated external shareholders. Visit www.nb.com for more information, including www.nb.com/disclosure-global-communications for information on awards.
Data as of March 31, 2026.

Media Contacts:
US: Soogyung Jordan: Soogyung.Jordan@nb.com
EMEA: Fiona Kehily: Fiona.Kehily@nb.com

All Neuberger figures are as of March 31, 2026, unless otherwise noted, and are subject to change without notice. The firm data, including employees and assets under management, reflect the collective data of the various affiliated investment advisors who are subsidiaries of Neuberger Berman Group LLC. The company history/timeline includes the history of all the company’s subsidiaries, including predecessor companies and acquisitions.

This material is issued on a limited basis through various global subsidiaries and affiliates of Neuberger Berman Group LLC. Please visit www.nb.com/disclosure-global-communications to learn about each company and the legal restrictions and restrictions. The name “Neuberger Berman” and logo are registered service marks of Neuberger Berman Group LLC.

© 2026 Neuberger Berman Group LLC. All rights reserved.

This press release appears as a matter of record only and does not constitute an offer to sell or a solicitation of an offer to purchase any security.

NBPE is established as a closed-end investment company domiciled in Guernsey. NBPE has received the necessary consent of the Guernsey Financial Services Commission. The value of investments may fluctuate. Results achieved in the past are no guarantee of future results. This document is not intended to constitute legal, tax or accounting advice or investment recommendations. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decision. Statements contained in this document that are not historical facts are based on current expectations, estimates, projections, opinions and beliefs of NBPE’s investment manager. Such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon. Additionally, this document contains “forward-looking statements.” Actual events or results or the actual performance of NBPE may differ materially from those reflected or contemplated in such targets or forward-looking statements.

        PRESS RELEASE

                Paris, 17 September 2026

Ramsay Santé Group unveils “Connecting Care 2030” to drive next phase of profitable growth and create long term value for all stakeholders

  • “Connecting Care 2030”, Ramsay Santé Group’s new strategic roadmap, leverages the transformation achieved through the successful execution of previous plan “Yes We Care 25”
  • The updated strategy is built on five pillars that will drive both operational and financial performance, all anchored in medical excellence and Ramsay Santé Group’s unwavering ambition to deliver quality care, at every step, for everyone
  • The new plan offers a clear path towards sustained topline growth and gradual margin improvement underpinned by a disciplined capital investment policy to strengthen its platform, support innovation and invest in the future of Healthcare
    • FY2029: Revenue growth1 c.3.0% per annum2 and EBITDA margin gradually improving
    • Continued deleveraging, targeting Net debt3/EBITDA (pre-IFRS) <4.0x

Paris, September 17th, 2026 – Ramsay Générale de Santé (“Ramsay Santé”) is hosting today its 2026 Capital Markets Day and presenting “Connecting Care 2030,” its new four-year strategic roadmap. The plan is designed to leverage the Group’s integrated European Healthcare platform, to improve patient outcomes and access to care while delivering sustainable profitable growth. It is anchored in Ramsay Santé Group’s ambition to deliver quality care, at every step, for everyone.

Next chapter of profitable growth and value creation for all stakeholders

Through the disciplined execution of its previous strategic plan, “Yes We Care 2025”, Ramsay Santé Group has grown in 5 years into a leading European Healthcare player, with differentiated positions in five countries including France and Sweden, serving more patients (from 9 to 13 million), establishing more care facilities (from 375 to 491) and patient satisfaction (NPS) rose by 2 points to reach +73.

Building on these achievements, Connecting Care 2030 puts medical excellence and patient-centered care at the heart of Ramsay Santé Group’s next phase of development while providing a clear path towards solid organic growth and sustainable margin expansion, through five clear strategic pillars:

  • Strengthen the integrated and accessible Healthcare offering,
  • Embrace the digital transformation of Healthcare delivery,
  • Ensure active portfolio and contract management,
  • Continue to focus on cost initiatives measures,
  • Accelerate additional profitable growth through new revenue streams.

Pascal Roché, CEO of Ramsay Santé Group, commented: “Today, we are opening the next chapter of Ramsay Santé Group’s development with “Connecting Care 2030”, our new strategic plan designed to unlock the full potential of our Group. These past years we have successfully transformed the Group, building one of the leading and most integrated Healthcare platform in Europe. Connecting Care 2030 is about unlocking the full potential of that platform with a clear ambition: connecting more patients across a greater share of their care journey, expanding where we have structural headroom, developing new revenue streams, and leveraging digitalisation and productivity to translate growth into stronger profitability.

At the heart of this strategy is medical excellence, which underpins everything we do: continuously improving patient outcomes and safety, sharing best practices across our European network, and scaling clinical innovation, research and training. This commitment makes us the partner of choice for patients, physicians and employees, and a trusted reference partner for governments and healthcare systems, reflecting our critical role in delivering accessible and high-quality care across our markets.

Leveraging a unique model of cross-country innovation and knowledge sharing, “Connecting Care 2030” provides a clear path towards sustained organic growth, progressive margin improvement and continued deleveraging, supported by disciplined capital allocation, ultimately creating sustainable long-term value for all our stakeholders.”

Opportunities for new shareholders, alongside long-term shareholder Crédit Agricole Assurances4

The Capital Markets Day marks a new chapter for Ramsay Santé Group, as Ramsay Health Care (RHC), its current 52.79% majority shareholder, has announced its intention to distribute its entire stake in Ramsay Santé Group to its own shareholders. It should be done through an in-specie distribution expected to be implemented in December of this year5 and could result in a significantly broader shareholder base. Ramsay Santé has applied for a foreign exempt listing on the Australian Securities Exchange (ASX) through CHESS Depository Interests (CDIs).

With a long-time independent strategy, financing and governance framework, the Group enters this new phase from a solid financial position, further reinforced by its recent refinancing. In addition, Crédit Agricole Assurances6, which holds 39.82% of Ramsay Santé Group, has reaffirmed its commitment as a long-term shareholder and its confidence in the Group’s strategy, management and development potential.

A leading European healthcare platform

These last few years, Ramsay Santé Group has grown into a leading European Healthcare platform, with strong positions and systemic relevance. It operates in compelling European healthcare markets, underpinned by favourable demographics, powerful secular growth trends and high barriers to entry. Its leadership is underpinned by a number of distinctive strengths:

  • Leading Healthcare platform of scale with systemic relevance
  • Truly integrated care offering, anchored in medical excellence
  • Partner of choice for patients, payors, doctors and employees
  • At the forefront of digi-physical care and AI innovation to improve access, clinical decision-making, efficiency and continuity of care
  • Solid financial performance with clear strategy and achievable milestones
  • Highly experienced management team

As a mission-driven company creating lasting impact, Ramsay Santé Group has built a diversified and integrated care offering anchored in medical excellence and a proven model of cross-country digital innovation and knowledge sharing.

Throughout the last 3 years, the Group has shown a resilient growth and earnings profile, underpinned by successful performance initiatives and a strengthened and flexible balance sheet:

  • Robust revenue growth in France, supported by sustained volume expansion in spite of a constrained tariff environment.
  • Solid organic growth in the Nordics, driven by positive price and volume trends in Primary care, growing St Göran revenues and sustained demand across Group’s specialist clinics.
  • Resilient profitability despite significant headwinds: successful performance plans have absorbed both the phase-out of temporary grants and underfunding of inflation.
  • Stronger financial structure following the successful refinancing: debt maturities extended to 2033, a simpler capital structure.
  • Significant financial flexibility from real estate, with €1.5bn of real-estate value.
  • Clear ongoing deleveraging trajectory.

The five strategic pillars of “Connecting Care 2030” support quality and sustainable performance

Strengthen the integrated and accessible Healthcare offering.

Ramsay Santé Group will leverage its unique integrated offering, spanning the entire patient pathway, multiple patient entry points and a well-positioned asset base across major urban areas. This provides meaningful headroom to deepen its presence in existing markets by scaling care facilities where it already has established capabilities, while building on the core MSO network through Primary care in Sweden, and the continued roll-out of imaging capabilities.

Embrace the digital transformation of Healthcare delivery.

Ramsay Santé Group will further digitalise care pathways and embed data and AI across the platform, improving both the patient journey and the way care is delivered. This includes tele-tools and remote care, AI-enabled Primary care pathways and revenue-cycle management, as well as the broader deployment of digital and AI tools to simplify administrative processes, support clinical decision-making and improve operational efficiency.

Ensure active portfolio and contract management.

Ramsay Santé Group will continue to actively manage its existing asset and contract base—not simply expand it—to concentrate resources where they can generate stronger growth and returns. Continued portfolio optimisation and rationalisation will support margin improvement through better capacity utilisation, closer alignment of the activity mix with evolving patient demand, and a leaner, more efficient network footprint.

Continue to focus on cost initiatives.

Ramsay Santé Group will further embed targeted performance initiatives across France and the Nordics, with margin improvement driven not simply by cost reduction but by better utilisation of existing capacity, enhanced occupancy rates of operating theatres, better medical staff efficiency, procurement optimisation, improved administrative costs, workforce planning improvement, and more efficient workflows.

Accelerate additional profitable growth through new revenue streams.

Beyond growth from its existing activities, Ramsay Santé Group will develop complementary revenue streams that leverage the strength of its Healthcare platform. This includes expanding home-based care and Mental health day care, and developing private health insurance and occupational health offerings in Sweden, creating additional sources of profitable growth around the Group’s core activities.

Short and mid-term financial outlook

By leveraging its integrated healthcare offering, strengthening the core MSO network and investing into complementary activities, Ramsay Santé expects to deliver solid organic growth in the coming years. In parallel, the group will implement multiple levers to improve profitability while driving robust cash-flow generation, through disciplined capital allocation and streamlined financing mix and costs. Its short- and mid-term financial outlook is as follows:

  • FY 2027: Revenue growth7 between 2.0% to 3.0% and stable EBITDA margin (vs. FY 2026)
  • FY 2029: Revenue growth7 at c. 3.0% per annum8 and gradual EBITDA margin improvement
  • Gross capex at approximately 4.0% of revenue on average over the FY 2027-FY 2029 period.
  • Continued deleveraging, targeting net debt9 / EBITDA (pre-IFRS) below 4.0x.

The slide deck presentation and the Webcast of the Capital Markets Day are available here Webcast link and on our website Ramsay Santé EU AnalystsPresentation

Disclaimer

This press release may contain certain statements that are forward-looking. Such forward-looking statements are for illustrative purposes only. Such forward-looking statements involve significant risks, uncertainties and assumptions that could cause actual results to differ materially from the Company’s present expectations or projections, many of which are difficult to predict and generally beyond the control of Ramsay Santé. These risks and uncertainties include those discussed or identified under Chapter 3 of the Universal Registration Document of Ramsay Santé, filed with the French Autorité des marchés financiers (“AMF”) on 29th October 2025 under number D.25-0689 which is available on the websites of Ramsay Santé (www.ramsaysante.fr) and of the AMF (www.amf-france.org). Actual results and developments may differ materially from those expressed in, implied by or projected by forward-looking statements. Ramsay Santé does not undertake to update or revise the forward-looking statements that may be presented in this press release to reflect new information, future events or for any other reason. Any opinion expressed in this press release is subject to change without notice.

This press release does not contain or constitute an offer of securities for sale or an invitation or inducement to invest in any securities or other financial products in Ramsay Santé, in France, Australia, the United States or any other jurisdiction.

This press release is not intended to pre-empt the key disclosures that will be made in the demerger scheme booklet to be distributed by RHC (Demerger Booklet). Any decision made by RHC shareholders in connection with the proposed distribution should be made only on the basis of the Demerger Booklet. This press release is not relevant to and should not be relied upon in connection with voting on the proposed demerger.

About Ramsay Santé

Ramsay Santé is the European leader in private hospitalisation and primary care. With 40,000 employees and 10,000 practitioners, the group welcomes 13 million patients each year in 491 facilities across five countries (France, Sweden, Norway, Denmark and Italy).

As a mission-driven company, Ramsay Santé covers the entire care pathways in medicine, surgery, obstetrics, medical and rehabilitation care, mental health and primary care centers, with constant innovation to improves everyone’s health and ensures equitable access to secure and qualitative care.

Facebook: https://www.facebook.com/RamsaySante 
Instagram: https://www.instagram.com/ramsaysante 
LinkedIn: https://www.linkedin.com/company/ramsaysante 
YouTube: https://www.youtube.com/c/RamsaySante 

Code ISIN and Euronext Paris: FR0000044471 
Website:  www.ramsaysante.fr 

Investor / Analyst Relations        Press Relations

Clément Lafaix        Brigitte Cachon
Tél. +33 1 87 86 21 52        Tél. +33 1 87 86 22 11
clement.lafaix@ramsaysante.fr        brigitte.cachon@ramsaysante.fr


1 Excluding FX effect
2 CAGR FY2026-2029
3 Based on latest known tax framework (refer to page 4)
4 Through its subsidiary Predica.
5 The distribution is subject to satisfaction of customary conditions including RHC Board, RHC shareholder, Australian court and regulatory approvals.
6 Crédit Agricole Assurances confirmed that it did not intend to increase its shareholding in the Company or take control of it

7 Excluding FX effect
8 CAGR FY2026-2029
9 Based on latest known tax framework; in France, CVAE (Corporate Value-Added Tax) maintained over FY27-FY29; no renewal of the temporary/special CIT levy assumed after 2026

Attachment

17 September 2026

ICG plc (the “Company”)

Transaction in Own Shares, Completion of Share Buyback Programme and Total Voting Rights

The Company announces that on 9 September 2026, in accordance with the terms of its share buyback programme announced on 19 February 2026 (the “Share Buyback”), the Company has purchased 72,916 ordinary shares of nominal value of £0.2625 each in the capital of the Company (the “Ordinary Shares“) on the London Stock Exchange through Merrill Lynch International (“BofA Securities”).

The Share Buyback is to enable the Company to issue Ordinary Non-Voting shares to Amundi equal to the number of Ordinary Shares repurchased by the Company in a manner that is non-dilutive to the Company’s existing shareholders in connection with its strategic partnership with Amundi as announced on 18 November 2025 (the “Strategic Partnership Announcement”).

Aggregated Information

Date of Purchase: Aggregate Number of Ordinary Shares Purchased: Lowest Price Paid per Ordinary Share (GBP): Highest Price Paid per Ordinary Share (GBP): Volume-Weighted Average Price Paid per Ordinary Share (GBP):
9 September 2026 72,916 1914.00 pence 1981.00 pence 1941.95 pence

The Ordinary Shares acquired were initially held in Treasury and subsequently cancelled.

Schedule of Purchases

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the “Market Abuse Regulation”), (as in force in the UK and as amended by the Market Abuse (Amendment) (EU Exit) Regulations 2019), a full breakdown of the individual trades made by BofA Securities on behalf of the Company as part of the programme is detailed on the attached:

ICG PLC Weekly Trade Fills

Completion of Share Buyback Programme

The Company confirms that, following the purchase of the Ordinary Shares disclosed above, the Share Buyback has now concluded. Since the commencement of the Share Buyback, the Company has repurchased 15,280,825 Ordinary Shares in aggregate at a weighted average price of 1790.56 pence per Ordinary Share for a total consideration of approximately £274 million. In accordance with the Subscription Agreement, Amundi has subscribed for an equivalent number of Ordinary Non-Voting shares. The subscription price for those Ordinary Non-Voting shares was equal to the repurchase price for the Ordinary Shares, and Amundi will reimburse the Company in cash for the costs and expenses incurred in connection with the Share Buyback.

As a result of the completion of the Share Buyback, Amundi has a 9.9% economic interest in the Company, including a 4.9% voting interest. The Ordinary Shares and Ordinary Non-Voting shares have the same economic entitlements, including as relates to dividends. Shareholders may therefore use the figure of 290,644,122 (being the combined number of Ordinary Shares and Non-Voting Ordinary shares outstanding) to assess their economic interest in the Company.

Cancellation of Treasury Shares and Total Voting Rights

The Company confirms that on 16 September 2026, following the completion of the Share Buyback, it cancelled 6,897,364 Ordinary Shares held in Treasury. Following the cancellation, the Company has 275,363,297 Ordinary Shares in issue and 15,280,825 Ordinary Non-Voting shares in issue.

Therefore, the total number of voting rights in the Company is 275,363,297, and this figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.

No Ordinary Shares or Ordinary Non-Voting shares are currently held in Treasury.

Terms not defined here shall have the meaning as set out in the Strategic Partnership Announcement.

Enquiries:

Chris Hunt, Head of Corporate Development and Shareholder Relations, ICG
+44 (0) 20 3545 2020

Media:

Fiona Laffan, Global Head of Corporate Affairs, ICG
+44(0)20 3545 1510

Attachment

Not for release, publication or distribution, in whole or in part, directly or indirectly in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction

Oslo, 17 September 2026 – DNO ASA, the Norwegian oil and gas operator, announces that the boards of DNO, DNO Bidco AS and Capricorn Energy plc have agreed a revision to the terms of the Acquisition announced on 1 September 2026 pursuant to which Capricorn Shareholders will be entitled to receive an amount equal to the full Acquisition Value in cash from Bidco.

The boards of the three companies believe that the Revised All-Cash Offer provides Capricorn Shareholders with greater certainty of value as compared to the Original Offer, as it is not reliant on the Capricorn Board being able to declare and pay the Permitted Dividend in full prior to the Effective Date.

The Capricorn Directors intend to recommend unanimously that Capricorn Shareholders vote in favour of the Scheme at the Court Meeting and the resolutions to be proposed at the General Meeting, each to be convened as soon as practicable.

The full announcement is attached.

– 

For further information, please contact:
Media: media@dno.no
Investors: investor.relations@dno.no

– 

DNO ASA is a Norwegian oil and gas operator active in the North Sea and the Middle East. Founded in 1971, DNO is Norway’s oldest oil company and the first to list on the Oslo Stock Exchange in 1981. The Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in Norway, the Kurdistan region of Iraq, the United Kingdom and Yemen. More information is available at www.dno.no.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Attachment

ICG Enterprise Trust plc (the “Company”)

17 September 2026

Transaction in Own Shares

The Company announces that on 16 September 2026 it bought back 15,000 of its own shares under the long-term buyback programme, to be held as treasury shares, at an average price of 1408 pence per share.

Further details are set out below:

  • Number of shares held as treasury shares following settlement of this purchase: 3,194,951
  • Total shares in issue excluding treasury shares following settlement of this purchase: 60,359,241

The Company has bought back these shares under the authority granted by shareholders at its Annual General Meeting in June 2026, which permits the Company to repurchase a maximum of 14.99% of its ordinary shares. The actual number of shares repurchased by the Company will depend on market conditions. This authority lasts until the next shareholder authority granted (expected to be at the Annual General Meeting in 2027), or until expressly revoked by shareholders.

No maximum consideration payable has been determined by the Company, but the Company is unable to pay a price for any shares pursuant to the buyback which would equate to a premium to the net asset value. It is the Company’s current intention to hold any shares bought back in treasury.

The Company has instructed Numis Securities Limited (trading for these purposes as Deutsche Numis) as its broker in respect of its buyback transactions. This arrangement is in accordance with the UKLA Listing Rules and the Company’s general authority to repurchase shares.

Analyst / Investor enquiries:

Chris Hunt
Shareholder Relations, ICG
+44 (0) 20 3545 2020

Andrew Lewis
Company Secretary, ICG
+44 (0) 20 3545 1344

Media:

Clare Glynn
Corporate Communications, ICG
+44 (0) 20 3545 1395

Bang & Olufsen A/S has, pursuant to the Danish Capital Markets Act, received a major shareholder notification from UBS Group AG.

  • As per 11 September 2026, UBS Group AG’s holding of shares and voting rights pursuant to section 38 of the Danish Capital Markets Act, as well as other financial instruments pursuant to section 39(2), was below 5 percent of the total share capital and voting rights in Bang & Olufsen A/S.

As of 11 September 2026, UBS Group AG held a total of 7,347,988 shares and voting rights in Bang & Olufsen A/S, corresponding to 4.99 percent of the total share capital and voting rights.

For further information, please contact:

Cristina Rønde Hefting
Sr. Director, Head of Strategy & Investor Relations
Phone: +45 4153 7303

Attachment

COPENHAGEN, Denmark, September 17, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that Tarja Stenvall has been appointed President and Chief Executive Officer, effective October 15, 2026, succeeding Paul Chaplin whose departure was announced earlier this year.

Tarja Stenvall is a global healthcare executive with over 20 years of leadership experience from Sanofi, AstraZeneca, and Pfizer, combining deep commercial expertise with a proven track record of building and transforming businesses at scale. She has held country, regional, and global roles across specialty care, general medicines, and vaccines, leading organizations of more than 3,000 people and having more than 3 billion euros profit-and-loss responsibility.

Chair of the Board of Directors, Anne Louise Eberhard, said: “Following a comprehensive search, the Board is pleased to appoint Tarja Stenvall as new Chief Executive Officer of Bavarian Nordic. Tarja Stenvall brings a proven ability to scale and lead a global life science business, combining strategic vision with deep experience from global pharma and vaccines industry and passion for improving and protecting lives. Bavarian Nordic is entering the next chapter from a position of strength. We have a clear purpose, and we will continue to scale our unique platform addressing infectious disease and improve the resilience of public health. The Board trusts Tarja to be the right profile to lead Bavarian Nordic. On behalf of the Board, I would also like to express our sincere appreciation to Paul Chaplin for his many years of dedicated leadership and profound impact on Bavarian Nordic. Under his leadership, the company evolved from a research-focused organization into a global vaccines company that today plays an important role in securing public health worldwide.”

Tarja Stenvall
said: “The opportunity to join Bavarian Nordic is tremendously exciting. What attracted me to Bavarian Nordic is its unique combination of a strong scientific foundation, a proven global manufacturing and supply chain and commercial platform. The company has built a leading position in vaccines while remaining firmly committed to improving and protecting lives, making this a truly compelling opportunity. Throughout my career in the life sciences and vaccine industry, I have been passionate about translating scientific innovation into meaningful patient impact by building global organizations and delivering long-term value and sustainable growth. I believe the company has a strong foundation for its next phase of growth, and I am excited by the opportunity to expand the global impact of Bavarian Nordic’s vaccines while continuing to strengthen the company’s position as a leading global vaccine company.”

Effective October 15, 2026, the Executive Management of Bavarian Nordic will consist of the following:

  • Tarja Stenvall, President & Chief Executive Officer
  • Henrik Juuel, EVP & Chief Financial Officer
  • Jean-Christophe May, EVP & Chief Commercial Officer
  • Russell Thirsk, EVP & Chief Operating Officer

About Tarja Stenvall
Tarja Stenvall is a senior pharmaceutical executive recognized for leading large-scale organizations across Europe, Latin America, and global markets. Throughout a career spanning more than two decades, she has held senior leadership positions at Sanofi, AstraZeneca, and Pfizer, building a reputation for driving sustainable growth, organizational transformation, and improved patient access to innovative medicines and vaccines.

She most recently served as Senior Vice President and Head of Global Franchise for diabetes and cardiovascular diseases at Sanofi, where she oversaw global portfolio strategy and long-term planning for a €10B franchise. Prior to this role, she held several senior leadership positions within Sanofi, including Senior Vice President for Key Markets in General Medicines, Senior Vice President for Europe, and Vice President for Vaccines in Latin America where she secured Sanofi’s largest global private-public partnership. During her tenure with Sanofi, she served as member of the Global Business Unit Leadership Team and the Global Sanofi Sustainability Impact Committee.

Prior to joining Sanofi in 2014, Tarja held various commercial leadership roles with increasing responsibility at AstraZeneca and has also held commercial leadership positions in Pfizer.

Tarja Stenvall holds a degree in Economics from Aalto University (formerly the Helsinki School of Economics and Business Administration) in Finland, and an MBA in International Business from the University of South Carolina in the US.

Images for the press are available on the company’s website:
https://www.bavarian-nordic.com/media/media/ceo.aspx

About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contact investors:
Anders Hjort, Head of Investor Relations, ahjo@bavarian-nordic.com, Tel. +45 44 74 99 58
Graham Morrell, Gilmartin Group, graham@gilmartinir.com, Tel: +1 781 686 9600

Contact media:
Nicole Seroff, Vice President Corporate Affairs, nise@bavarian-nordic.com, Tel: +45 53 88 06 03

Company Announcement no. 43 / 2026

This announcement contains publication of inside information pursuant to Article 17 of the EU Market Abuse Regulation.

Attachment

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.